CERS Cerus Corporation

NASDAQ

$2.62

Cerus Corporation (CERS) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is a loss of $0.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.8% since its last earnings release on July 30, 2026.

Cerus Reported Earnings, Narrows Guidance

Thursday, July 30, 2026 · 4:01 PM ET

3rd Quarter, Sep 2026

Monday · 4:00 PM ET

Earnings Whisper

-

vs ($0.01)

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $2.53

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cerus Corporation

Cerus Corp is a biomedical products company. It is engaged in developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.